
Jazz Pharmaceuticals (JAZZ): Oncology Growth Meets Cash Flow
Jazz Pharmaceuticals posted record third-quarter revenue, with oncology and Xywav driving growth while the stock still trades at a modest forward multiple. The thesis is balanced by heavy debt, product concentration, and looming competition.

